• Creative Medical Technology Holdings posted a Q2 net loss of USD 1.51 million, widening from USD 1.23 million a year earlier.
• Selling, general and administrative expense climbed 48% to USD 1.08 million, driven by higher marketing spend tied to a company-level campaign.
• Research and development expense fell 8% to USD 459,200 as the CELZ-201 ADAPT trial moved into follow-up, partly offset by broader platform investment.
• Other income rose to USD 50,913 from USD 30,217 on higher short-term investment balances, while no revenue was generated.
• FDA cleared an ADAPT trial expansion in June to add patients with ongoing opioid use; cash and US Treasuries totaled USD 8.71 million at June 30.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Creative Medical Technology Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001477932-26-004779), on August 07, 2026, and is solely responsible for the information contained therein.